Docetaxel in the management of advanced pancreatic cancer

Seminars in Oncology

Volumn 32, Issue SUPPL. 4, 2005, Pages 10-23

  Lopes, Gilberto ^a   Rocha Lima, Caio Max S ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CAPECITABINE; CARBOPLATIN; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; FLUOROURACIL; GEMCITABINE; IRINOTECAN; RANITIDINE; THALIDOMIDE;

ADVANCED CANCER; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; DEPRESSION; DIARRHEA; DRUG CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG MONITORING; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; LEUKOCYTE COUNT; LEUKOPENIA; LUNG DISEASE; LUNG EMBOLISM; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PANCREAS CARCINOMA; PNEUMONIA; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

EID: 19444387950     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.04.003     Document Type: Article

References (73)

1. American Cancer Society Cancer Facts and Figures 2004 2004 American Cancer Society, Inc Atlanta, GA Available at: http://www.cancer.org (accessed June 1, 2004)
2. National Cancer Institute Pancreatic Cancer (PDQ): Treatment. Health Professional Version 2003 Available at: http://www.cancer.gov (accessed June 18)
3. D.J. Klaassen, J.M. MacIntyre, G.E. Catton Treatment of locally unresectable cancer of the stomach and pancreas A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study J Clin Oncol 3 1985 373 378
4. H.A. Burris III, M.J. Moore, J. Andersen Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer A randomized trial J Clin Oncol 15 1997 2403 2413
5. J.D. Berlin, P. Catalano, J.P. Thomas Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma Eastern Cooperative Oncology Group Trial E2297 J Clin Oncol 20 2002 3270 3275
6. V. Heinemann, D. Quietzsch, F. Gieseler A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma J Clin Oncol 22 suppl 2003 250 (abstr 1003)
7. C. Louvet, R. Labianca, P. Hammel Gemcitabine versus GEMOX (gemcitabine + oxaliplatin) in non resectable pancreatic adenocarcinoma Interim results of the GERCOR/GISCAD Intergroup Phase III Proc Am Soc Clin Oncol 22 2003 250 (abstr 1004)
8. Gemzar [package insert]. Indianapolis, IN, Eli Lilly and Company, 2003
9. E.M. O'Reilly, G.K. Abou-Alfa, R. Letourneau A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer (APC) Proc Am Soc Clin Oncol 22 2004 315s (abstr 4006)
10. D.A. Richards, H.L. Kindler, H. Oettle A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer Proc Am Soc Clin Oncol 22 2004 315s (abstr 4007)
11. C.M.S. Rocha Lima, R. Rotche, M. Jeffery A randomized phase 3 study comparing efficacy and safety of gemcitabine (GEM) and irinotecan (I), to GEM alone in patients (pts) with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy Proc Am Soc Clin Oncol 22 2003 251 (abstr 1005)
12. S.R. Bramhall, J. Schulz, J. Nemunaitis A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer Br J Cancer 87 2002 161 167
13. E. Van Cutsem, P. Karasek, H. Oettle Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC) Proc Am Soc Clin Oncol 21 2002 130a (abstr 517)
14. J.E. Cortes, R. Pazdur Docetaxel J Clin Oncol 13 1995 2643 2655
15. M.-C. Bissery, D. Guénard, F. Guéritte-Voegelein Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue Cancer Res 51 1991 4845 4852
16. N. Androulakis, C. Kourousis, M.A. Dimopoulos Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor A multicenter phase II study J Clin Oncol 17 1999 1779 1785
17. R. Lenzi, S. Yalcin, D.B. Evans Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy Cancer Invest 20 2002 464 472
18. S. Okada, Y. Sakata, S. Matsuno Phase II study of docetaxel in patients with metastatic pancreatic cancer A Japanese cooperative study Br J Cancer 80 1999 438 443
19. P. Preusser, N. Niederle, A. Harstrick Phase II study of docetaxel as first line chemotherapy in metastatic adenocarcinoma of the pancreas Proc Am Soc Clin Oncol 18 1999 297a (abstr 1142)
20. P. Rougier, A. Adenis, M. Ducreux A phase II study Docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma Eur J Cancer 36 2000 1016 1025
21. A. Lück, K. Ridwelski, H. Lippert Phase I study of a treatment with gemcitabine and docetaxel weekly in advanced pancreatic cancer Ann Hematol 77 suppl 2 1998 S48 (abstr 190)
22. A. Lueck, K. Ridwelski, E. Kettner Final results of a phase I study of weekly gemcitabine and docetaxel in pancreatic carcinoma and preliminary results of a phase II study Proc Am Soc Clin Oncol 19 2000 318a (abstr 1256)
23. K.N. Ganjoo, M.S. Gordon, A.B. Sandler A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer A Hoosier Oncology Group study Oncology 62 2002 299 304
24. D.P. Ryan, T.J. Lynch, M.L. Grossbard A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors Cancer 88 2000 180 185
25. M.E. Poole, S.A. Bernard, M.A. Churchel Phase I study of gemcitabine and docetaxel for advanced stage solid tumors Cancer Invest 21 2003 350 354
26. M.J. Boyer, D. Rischin, M.J. Millward Phase I study of gemcitabine (G) and docetaxel (D) in patients (pts) with advanced cancer Proc Am Soc Clin Oncol 18 1999 204a (abstr 785)
27. J.R. Rigas, M.L. Rothenberg, T.H. Davis Phase I clinical and pharmacokinetic study of docetaxel in combination with two gemcitabine infusion schedules Proc Am Soc Clin Oncol 18 1999 226a (abstr 870)
28. M.P. Lutz, M. Ducreux, T. Wagener Docetaxel/gemcitabine or docetaxel/cisplatin in advanced pancreatic carcinoma A randomized phase II study of the EORTC-GI group Proc Am Soc Clin Oncol 21 2002 125a (abstr 498)
29. Greek Cooperative Group for Pancreatic Cancer N. Androulakis, G. Stathopoulos, N. Tsavaris First line treatment with docetaxel (D) and gemcitabine (G) in patients with inoperable pancreatic cancer A multicenter phase II study Eur J Cancer 35 suppl 4 1999 S142 (abstr 521)
30. A.D. Jacobs, H. Otero, V. Picossi Jr A phase I/II study of gemcitabine (G) and docetaxel (D) in patients (pts) with unresectable pancreatic cancer Proc Am Soc Clin Oncol 19 2000 265a (abstr 1032)
31. B.P. Schneider, K.N. Ganjoo, D.E. Seitz Phase II study of gemcitabine and docetaxel in combination for advanced pancreatic cancer--A Hoosier Oncology Group study Proc Am Soc Clin Oncol 21 2002 137a (abstr 546)
32. C. Schmidt, J. Fahlke, E. Kettner Combination chemotherapy with gemcitabine and docetaxel in patients with inoperable or metastatic pancreatic cancer A multicenter phase II study Proc Am Soc Clin Oncol 22 2003 358 (abstr 1439)
33. D.P. Ryan, M.H. Kulke, C.S. Fuchs A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma Cancer 94 2002 97 103
34. M. Gonzalez Cao, E. Salgado, J. Rodríguez Docetaxel (D) with gemcitabine (GEM) in metastatic pancreatic cancer Proc Am Soc Clin Oncol 20 2001 131b (abstr 2274)
35. W.H. Sherman, R.L. Fine Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas Oncology 60 2001 316 321
36. R.C. Shepard, D. Levy, K. Stuart Pancreatic cancer biweekly gemcitabine/docetaxel chemotherapy Proc Am Soc Clin Oncol 20 2001 154a (abstr 614)
37. Z. Petrovic Docetaxel and gemcitabine in patients with advanced pancreatic cancer Proc Am Soc Clin Oncol 20 2001 129b (abstr 2268)
38. K. Ridwelski, E. Kettner, L. Greiner Multicenter phase II study of weekly docetaxel and gemcitabine for the treatment of patients (Pts) with advanced or recurrent pancreatic cancer Proc Am Soc Clin Oncol 20 2001 157a (abstr 624)
39. G.P. Stathopoulos, D. Mavroudis, N. Tsavaris Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor A phase II study of the Greek Cooperative Group for Pancreatic Cancer Ann Oncol 12 2001 101 103
40. J. Clark, D. Ryan, M. Kulke Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic cancer Proc Am Soc Clin Oncol 19 2000 313a (abstr 1238)
41. J. Fahlke, K. Ridwelski, C. Schmidt Combination chemotherapy with docetaxel and gemcitabine in patients with metastatic or locally advanced pancreatic carcinoma Results of a multicenter phase II study J Clin Oncol 22 suppl 2004 338s (abstr 4101)
42. M.H. Kulke, D. Niedzwiecki, M.A. Tempero A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CALBG 89904) J Clin Oncol 23 suppl 2004 315 (abstr 4011)
43. G.S. Long, M.F. Earle, T.L. Evans Phase I study of gemcitabine, docetaxel and carboplatin triple drug combination (GDC), with and without filgrastim (G-CSF) support, in patients with advanced non-hematological malignancies Proc Am Soc Clin Oncol 19 2000 227a (abstr 890)
44. D. Wunderlich, T. Buechele, R. Zamoryn Biweekly docetaxel (DOC), gemcitabine (GEM) and oxaliplatin (LOHP) in pretreated patients with solid tumors. Results of a phase I study Proc Am Soc Clin Oncol 19 2000 221a (abstr 862)
45. R.L. Fine, W. Sherman, J. Chabot Biochemically synergistic chemotherapy for advanced pancreatic cancer (PC) Proc Am Soc Clin Oncol 21 2002 144a (abstr 575)
46. J.-E. Kurtz, S. Négrier, F. Husseini A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer Hepatogastroenterology 50 2003 567 570
47. C. Couteau, M.-L. Risse, M. Ducreux Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors J Clin Oncol 18 2000 3545 3552
48. B. Burtness, R. Edwards, E. Knill-Selby Preliminary evidence of activity from a phase II trial of docetaxel/irinotecan (D/I) combination in patients (pts) with advanced pancreatic cancer (PC) Int J Cancer 20 suppl 2002 245 (abstr P330)
49. T. Petit, C. Aylesworth, H. Burris A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies Ann Oncol 10 1999 223 229
50. M.F. Mulcahy, P.J. Loehrer, N.J. Meropol Phase I study of docetaxel, cisplatin, 5-FU and leucovorin Proc Am Soc Clin Oncol 20 2001 171a (abstr 682)
51. European Organization for Research and Treatment of Cancer: Phase II randomized study of docetaxel and gemcitabine versus docetaxel and cisplatin in metastatic or locoregionally advanced pancreatic carcinoma. Protocol EORTC-40984. Available at: www.cancer.gov. (accessed November 2004)
52. Camptosar [package insert]. New York, NY, Pfizer Inc, 2002
53. B. Burtness, R. Sipples, G. Mirto Phase II trial of irinotecan/docetaxel combination for advanced pancreatic cancer J Clin Oncol 23 suppl 2004 341 (abstr 4116)
54. C. Couteau, F. Lokiec, L. Vernillet Phase I dose-finding and pharmacokinetic (PK) study of docetaxel (D) in combination with irinotecan (I) in advanced solid tumors Proc Am Soc Clin Oncol 16 1997 202a (abstr 709)
55. Adrucil [package insert]. Kalamazoo, MI, Pharmacia and Upjohn Company, 2001
56. Xeloda [package insert]. Nutley, NJ, Roche Pharmaceuticals, 2003
57. H. Frucht, P.D. Stevens, D.R. Fogelman Advances in genetic screening, work-up, and treatment of pancreatic cancer Curr Treat Options Gastroenterol 7 2004 343 354
58. D.R. Fogelman, S. Schreibman, R.L. Fine Effective salvage therapy (T-GX) for pancreatic cancer patients after treatment with GTX J Clin Oncol 22 suppl 2004 380s (abstr 4268)
59. Arora A, Lynch J, Brand R,, et al. Phase I trial of docetaxel plus thalidomide in patients with progressive pancreatic adenocarcinoma after gemcitabine-based therapy [abstract 142]. Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, June 5-8, 2004, New Orleans, LA
60. E.S. Kim, F.R. Khuri Docetaxel and radiation as combined-modality therapy Oncology 16 suppl 2002 97 105
61. F. Viret, M. Ichou, M. Giovannini A phase I trial of simultaneous weekly docetaxel and radiotherapy in patients with locally advanced adenocarcinoma of the pancreas Proc Am Soc Clin Oncol 21 2002 166a (abstr 660)
62. J.M. Pipas, R.J. Barth, B. Zaki Docetaxel/gemcitabine followed by gemcitabine and radiotherapy in patients with pancreatic adenocarcinoma Proc Am Soc Clin Oncol 22 2003 347 (abstr 1392)
63. J.M. Pipas, R.J. Barth, B. Zaki Docetaxel/gemcitabine followed by gemcitabine and radiotherapy in patients with pancreatic adenocarcinoma J Clin Oncol 22 suppl 2004 340s (abstr 4109)
64. S. Amat, P. Bougnoux, F. Penault-Llorca Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate Br J Cancer 88 2003 1339 1345
65. A.W. Hutcheon, S.D. Heys, T.K. Sarkar Neoadjuvant docetaxel in locally advanced breast cancer Breast Cancer Res Treat 79 suppl 1 2003 S19 S24
66. D.C. Betticher, S.F. Hsu Schmitz, M. Totsch Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer A multicenter phase II trial J Clin Oncol 21 2003 1752 1759
67. K.V. Mattson, R.P. Abratt, G. ten Velde Docetaxel as neoadjuvant therapy for radically treatable stage II non-small-cell lung cancer A multinational randomised phase III study Ann Oncol 14 2003 116 122
68. A.O. Greco, J.R. Eckardt, C. Kimminau An analysis of the outcome of patients with head and neck cancer treated with neoadjuvant docetaxel, platinum, fluorouracil, and leucovorin followed by definitive local therapy Proc Am Soc Clin Oncol 22 2003 519 (abstr 2088)
69. F.M. Johnson, A. Garden, M. Kies A phase II study of docetaxel (D) and carboplatin (C) as neoadjuvant therapy for patients with low T, high N stage nasopharyngeal carcinoma (NPC) Proc Am Soc Clin Oncol 22 2003 510 (abstr 2053)
70. M. Hussain, D.C. Smith, B.F. El-Rayes Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer Urology 61 2003 774 780
71. M.F. Gnant, I. Kuehrer, B. Teleky Neoadjuvant chemotherapy with gemcitabine and docetaxel for locally advanced pancreatic cancer Proc Am Soc Clin Oncol 21 2002 149a (abstr 593)
72. M. Gnant, I. Kuehrer, B. Teleky Effect of neoadjuvant chemotherapy with gemcitabine and docetaxel on 3-year survival and resection rate in previously unresectable locally advanced pancreatic cancer J Clin Oncol 22 suppl 2004 371s (abstr 4234)
73. Eastern Cooperative Oncology Group: Irinotecan and docetaxel with or without cetuximab in treating patients with metastatic pancreatic cancer. Protocol ECOG-E8200. Available at: www.clinicaltrials.gov (accessed November 2004)